US EditionPublished • loading... • Updated
HSE approves Bayer’s Beyonttra (acoramidis) for reimbursement as a new treatment of transthyretin amyloidosis in adult patients with cardiomyopathy
Summary by Irish Medical Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
HSE approves Bayer’s Beyonttra (acoramidis) for reimbursement as a new treatment of transthyretin amyloidosis in adult patients with cardiomyopathy
ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure The post HSE approves Bayer’s Beyonttra (acoramidis) for reimbursement as a new treatment of transthyretin amyloidosis in adult patients with cardiomyopathy appeared first on Irish Medical Times.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
